Quinazoline compounds

摘要

The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is -O-, -NH- or -S-; n is 0-5; m is 0-3; R¹ and R² are defined herein including groups: (i) Q¹X¹ wherein Q¹ and X¹ are as defined herein; (ii) Q¹⁵W³ wherein Q¹⁵ and W³ are as defined herein, (iii) Q²¹W⁴C_1-5alkylX¹- wherein Q²¹, W⁴ and X¹ are as defined herein, (iv) Q²⁸C_1-5alkylX¹-, Q²⁸C_2-5alkenylX¹- or Q²⁸C_2-5alkynylX¹- wherein Q²⁸ and X¹ are as defined herein and (v) Q²⁹C_1-5alkylX¹-, Q²⁹C_2-5alkenylX¹- or Q²⁹C_2-5alkynylX¹- wherein Q²⁹ and X¹ are as defined herein; R² can also be 6,7-methylenedioxy or 6,7-ethylenedioxy; and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm?blooded animals; processes for the preparation of such compounds; intermediates used in such processes; processes for making such intermediates; pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of formula I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.